EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 30 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR New analysis estimates over 21 million UK adults will be obese... May 18, 2022 ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung... June 4, 2023 New on NCI’s Websites, March 2020 March 16, 2020 First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... July 21, 2023 Load more HOT NEWS Lo que deben saber las personas con cáncer de mama y... Do Cancer Survivors Have To Be Positive All the Time? Letting... FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy A bug in the system – the difficulties of linking the...
